STOCK TITAN

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Jefferies London Healthcare Conference, taking place in-person on November 16th and 17th, 2021.

Jefferies London Healthcare Conference Presentation Information:
FormatLive presentation and 1-on-1 in person meetings
Speaker:Dr. Alon Seri-Levy, Chief Executive Officer
Date:Tuesday, November 16th 2021
Time:8:00-8:35 AM GMT
To ListenTo listen to the presentation, click here. A replay will be archived for 30 days at this link (or go to www.sol-gel.com to access within the Investors/Events and Presentations section).

About Sol-Gel Technologies

Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021.  Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed for U.S. commercialization with Galderma

The Company’s pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment of plaque psoriasis and other dermatologic indications.
For additional information, please visit www.sol-gel.com.

Contact:

Irina Koffler
Investor relations, LifeSci Advisors
ikoffler@lifesciadvisors.com
+1-917-734-7387

Sol-Gel Technologies
Gilad Mamlok
Chief Financial Officer
gilad.mamlok@sol-gel.com


Sol-Gel Technologies Ltd

NASDAQ:SLGL

SLGL Rankings

SLGL Latest News

SLGL Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Israel
7 Golda Meir

About SLGL

sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th